Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02704858 : Safety and Efficacy Study in Recurrent Grade IV Glioma
PhasePhase 1/Phase 2
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion Criteria:

- Radiographically-confirmed progression of, or recurrent, primary or secondary Grade IV
glioma, and must be on a stable or decreasing dose of steroid for at least five days
prior to the date of informed consent.

- Must have failed previous radiation treatment or combined treatment with temozolomide
and radiation.

- If progression of disease occurs within three months of conformal radiation, it must
be outside of the radiation field or proven by biopsy/resection.

- Must have an ECOG performance status of 0 - 2, or KPS = 60.

- Must have an expected survival of at least three months.

- Must be willing to provide blood samples for pharmacokinetic study

- Must have adequate organ and marrow function

- Female patients of child-bearing potential and male patients must agree to use
adequate contraception

- Must have the ability to understand, and the willingness to sign, a written informed
consent.

Exclusion Criteria:

- The size of the Grade IV glioma tumor is multi-focal and > 30mm in size, as assessed
at the baseline (pre-study) MRI evaluation.

- Patient has completed chemo-radiation within the last three months, unless new
contrast enhancement is outside of radiation field, or there is tissue proven
recurrence or progression.

- Patient has had surgery within seven days prior to the date of informed consent.

- Patient has had chemotherapy within 28 days prior to first administration of study
drug.

- Patient has not recovered from adverse events due to chemotherapy, immunotherapy, or
radiation therapy administered more than 28 days prior to first administration of
study drug.

- Patient has had prior treatment with bevacizumab, a chemotherapy wafer implant
(Gliadel), or any other FDA- approved chemotherapy except temozolomide.

- Patient has had more than one recurrence or progression of their tumors.

- Patient is receiving any other investigational agents.

- Patient has a history of allergic reactions attributed to perillyl alcohol.

- Patient has uncontrolled intercurrent illness

- Patient has a history of new diagnosis or treatment of cancer other than malignant
glioma within five years prior to start of the study, except for basal cell carcinoma
or squamous cell carcinoma.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02704858      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740